NCT03086395 - Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD) | Biotech Hunter

Timeline

Start Date

April 1, 2017

Primary Completion Date

January 1, 2018

Study Completion Date

January 1, 2021

Conditions

Post-transplant Lymphoproliferative DisorderPTLD

Interventions

DRUG

Obinutuzumab

Patients will be treated with a total of 2 cycles of obinutuzumab. Cycle 1 obinutuzumab dose is 1000 mg given intravenously (IV) on day 1, 8, 15. Cycle #1 day #1 dose of 1000 mg of obinutuzumab will be administered over 2 days. During Cycle 1, Day 1, 100 mg will be administered. On the following day (Cycle 1, Day 2), 900 mg will be administered. During cycle 2 patients will receive a single dose of obinutuzumab1000 mg IV on day 1. Cycle #2 will be given 21 days after the first cycle.